Prof. Serkan Özakbaş
MedicalPoint Izmir Hospital
Neurology
Request Call Back
Education
- 1994 – 1999 Specialization in Medicine Dokuz Eylul University, Faculty of Medicine, Turkey
- 1986 – 1992 Bachelor’s Degree Dokuz Eylul University, Faculty of Medicine, Turkey
Activities in Scientific Journals
- 2021 – Ongoing Journal of Multiple Sclerosis Research Editor-in-Chief
Memberships / Positions in Scientific Organizations
- 1999 – Ongoing Turkish Neurological Association Member
Congress and Symposium Participation Activities
- November 12, 2022 – November 13, 2022 7th Symposium on Cognition in Multiple Sclerosis
ModeratorIzmir, Turkey
- October 26, 2022 – October 28, 2022 ECTRIMS 2022
ParticipantAmsterdam, Netherlands
- June 25, 2022 – June 28, 2022 EAN Congress
ParticipantVienna, Austria
- May 18, 2022 – May 19, 2022 IMSCOGS 2022
ParticipantBordeaux, France
- April 02, 2022 – April 07, 2022 AAN 2022
ParticipantWashington, United States
Research
- Comparative efficacy of rituximab versus azathioprine in the treatment of MOG antibody-associated disease (MOGAD)
Authors: Şen S., KÜRTÜNCÜ M., Demir S., GÜNDÜZ T., Demirel E., Tütüncü M., et al.
Citations: Unknown, Year: 2025 - Effect of the synchronized telerehabilitation-based upper extremity training program on hand-arm functions in people with multiple sclerosis
Authors: Dastan S., ERTEKİN Ö., Özdoğar A. T., Kahraman T., Baba C., ÖZAKBAŞ S.
Citations: Unknown, Year: 2025 - Effect of Telerehabilitation-Based Motor Imagery Training on Pain and Related Factors in People With Multiple Sclerosis: Randomized Controlled Pilot Trial
Authors: Karakas H., Kahraman T., Özdoğar A. T., Baba C., Ozakbas S.
Citations: Unknown, Year: 2025 - First-year treatment response predicts the following 5-year disease course in patients with relapsing-remitting multiple sclerosis
Authors: Toscano S., Spelman T., Ozakbas S., Alroughani R., Chisari C. G., Lo Fermo S., et al.
Citations: Unknown, Year: 2025 - Prevalence and Magnitude of Perceived Dual-Task Difficulties in People With Multiple Sclerosis: An International Study
Authors: Abasıyanık Z., Pedullà L., Kahraman T., Soler B., Santoyo-Medina C., Tacchino A., et al.
Citations: Unknown, Year: 2025 - The relationship between work difficulties and physical disability, cognitive and social cognitive impairment and subcortical gray matter atrophy in persons with multiple sclerosis
Authors: Aslan T., Özdoğar A. T., Sagici O., ÖZAKBAŞ S.
Citations: Unknown, Year: 2024 - Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis
Authors: Roos I., Sharmin S., Malpas C., ÖZAKBAŞ S., Lechner-Scott J., Hodgkinson S., et al.
Citations: Unknown, Year: 2024 - Investigation of the Relationship Between Coping With the Disease and Afecting Cognitive, Physical, and Psychosocial Factors in People with Multiple Sclerosis
Authors: Sagici O., ÖZDOĞAR A. T., Aslan T., ÖZAKBAŞ S.
Citations: Unknown, Year: 2024 - Risk of hepatitis B virus reactivation in people with multiple sclerosis treated with ocrelizumab: an observational study from Turkey
Authors: ÇELİK M., Baba C., IRMAK Ç., Özbakbaş S., AVKAN OĞUZ V.
Citations: Unknown, Year: 2024 - Emulating randomised clinical trials in relapsing-remitting multiple sclerosis with non-randomised real-world evidence: an application using data from the MSBase Registry
Authors: Signori A., Ponzano M., Kalincik T., ÖZAKBAŞ S., Horakova D., Havrdova E. K., et al.
Citations: Unknown, Year: 2024 - Comparative Effectiveness of Natalizumab, Fingolimod, and Injectable Therapies in Pediatric-Onset Multiple Sclerosis: A Registry-Based Study
Authors: Spelman T., Simoneau G., Hyde R., Kuhelj R., Alroughani R., Ozakbas S., et al.
Citations: Unknown, Year: 2024 - Predictors of relapse severity in multiple sclerosis
Authors: Baba C., Abasiyanik Z., Simsek Y., Ozdogar A. T., Sagici O., Ozakbas S.
Citations: Unknown, Year: 2024 - Cognition as a parameter in monitoring the effect of multiple sclerosis relapse treatment: A prospective controlled study
Authors: Piri Cinar B., Baba C., Demir S., Uzunkopru C., Seferoglu M., Gungor Dogan I., et al.
Citations: Unknown, Year: 2024 - What might the COVID-19 pandemic in regard to people with neuromyelitis optica spectrum disorder teach us regarding the future?
Authors: Baba C., Yavas I., SAMADZADE U., ÖZDOĞAR A. T., ÖZAKBAŞ S.
Citations: Unknown, Year: 2024 - Is disease-modifying therapy use in multiple sclerosis a risk factor during the COVID-19 pandemic? A large cohort study
Authors: Ozakbas S., Baba C., Yavas I., SAMADZADE U., ÖZDOĞAR A. T.
Citations: Unknown, Year: 2024 - The impact of COVID-19 infection on multiple sclerosis disease course across 12 countries: a propensity-score-matched cohort study
Authors: Levitz D., Chao Foong Y., Sanfilippo P., Spelman T., Rath L., Roldan A., et al.
Citations: Unknown, Year: 2024 - Investigating the relationship of theory of mind and empathy with neuroimaging, neuropsychological, and neuropsychiatric data in persons with multiple sclerosis
Authors: Aslan T., ÖZDOĞAR A. T., Sagici O., Yigit P., Zorlu N., BORA İ. E., et al.
Citations: Unknown, Year: 2024 - Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis: recruitment challenges, potential bias, and statistical strategies
Authors: Li Y., Saul A., Taylor B., Ponsonby A., Simpson-Yap S., Blizzard L., et al.
Citations: Unknown, Year: 2024 - Risk of secondary progressive multiple sclerosis after early worsening of disability
Authors: Dzau W., Sharmin S., Patti F., Izquierdo G., Eichau S., Prat A., et al.
Citations: Unknown, Year: 2023 - Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial
Authors: Diouf I., Malpas C. B., Sharmin S., Roos I., Horakova D., Kubala Havrdova E., et al.
Citations: Unknown, Year: 2023 - Dual-task difficulties as a risk factor for unemployment in people with multiple sclerosis
Authors: Kahraman T., Temiz H., Abasiyanik Z., Baba C., ÖZAKBAŞ S.
Citations: Unknown, Year: 2023 - The risk of secondary progressive multiple sclerosis is geographically determined but modifiable
Authors: Sharmin S., Roos I., Simpson-Yap S., Malpas C., Sánchez M. M., ÖZAKBAŞ S., et al.
Citations: Unknown, Year: 2023 - Severe disease reactivation in seropositive neuromyelitis optica spectrum disorders patients after stopping eculizumab treatment
Authors: Sen S., Tuncer A., Terzi M., BÜNÜL S. D., Ozen-Acar P., Altunrende B., et al.
Citations: Unknown, Year: 2023 - Feasibility of Telerehabilitation-Based Pelvic Floor Muscle Training for Urinary Incontinence in People With Multiple Sclerosis: A Randomized, Controlled, Assessor-Blinded Study
Authors: Yavas I., Kahraman T., Sagici O., Ozdogar A. T., Yigit P., Baba C., et al.
Citations: Unknown, Year: 2023 - Disability accrual in primary and secondary progressive multiple sclerosis.
Authors: Harding-Forrester S., Roos I., Nguyen A., Malpas C. B., Diouf I., Moradi N., et al.
Citations: Unknown, Year: 2023 - Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis
Authors: Roos I., Hughes S., McDonnell G., Malpas C. B., Sharmin S., BOZ C., et al.
Citations: Unknown, Year: 2023 - A plain language summary on the effectiveness of cladribine tablets compared with other oral treatments for multiple sclerosis: results from the MSBase registry
Authors: Spelman T., ÖZAKBAŞ S., Alroughani R., Terzi M., Hodgkinson S., Laureys G., et al.
Citations: Unknown, Year: 2023 - Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation
Authors: Zhu C., Kalincik T., Horakova D., Zhou Z., Buzzard K., Skibina O., et al.
Citations: Unknown, Year: 2023 - Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis
Authors: Kalincik T., Sharmin S., Roos I., Freedman M. S., Atkins H., Burman J., et al.
Citations: Unknown, Year: 2023 - mRNA versus inactivated virus COVID-19 vaccines in multiple sclerosis: Humoral responses and protectivity—Does it matter?
Authors: Tütüncü M., Demir S., Arslan G., Dinç Ö., Şen S., GÜNDÜZ T., et al.
Citations: Unknown, Year: 2023 - Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis
Authors: Daruwalla C., Shaygannejad V., ÖZAKBAŞ S., Havrdova E. K., Horakova D., Alroughani R., et al.
Citations: Unknown, Year: 2023 - The comparative effectiveness of fingolimod, natalizumab, and ocrelizumab in relapsing-remitting multiple sclerosis
Authors: BOZ C., ÖZAKBAŞ S., Terzi M., KARABUDAK R., Sevim S., Turkoglu R., et al.
Citations: Unknown, Year: 2023 - Narrative review based on fingolimod therapy in pediatric MS.
Authors: Piri Cinar B., Konuskan B., Anlar B., Ozakbas S.
Citations: Unknown, Year: 2023 - Effects of prolonged walking on dual-task walking performance in persons with multiple sclerosis
Authors: Abasiyanik Z., Kahraman T., Veldkamp R., ERTEKİN Ö., Kalron A., ÖZAKBAŞ S., et al.
Citations: Unknown, Year: 2023 - Psychometric properties of three self-report questionnaires assessing dual-task difficulties in people with multiple sclerosis: A multicenter study within the RIMS network
Authors: Abasiyanik Z., Pedulla L., Kahraman T., D’Hooge M., Santoyo-Medina C., Soler B., et al.
Citations: Unknown, Year: 2023 - Association between work-related difficulties and dual-task ability in people with multiple sclerosis
Authors: Temiz H., Kahraman T., Abasiyanik Z., Baba C., ÖZAKBAŞ S.
Citations: Unknown, Year: 2023 - Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis
Authors: Diouf I., Malpas C. B., Sharmin S., Roos I., Horakova D., Havrdova E. K., et al.
Citations: Unknown, Year: 2023 - Comparative effectiveness in multiple sclerosis: A methodological comparison
Authors: Roos I., Diouf I., Sharmin S., Horakova D., Havrdova E. K., Patti F., et al.
Citations: Unknown, Year: 2023 - Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry
Authors: Spelman T., ÖZAKBAŞ S., Alroughani R., TERZİ M., Hodgkinson S., Laureys G., et al.
Citations: Unknown, Year: 2023 - Effect of exergaming in people with restless legs syndrome with multiple sclerosis: A single-blind randomized controlled trial.
Authors: Ozdogar A. T., Ertekin Ö., Kahraman T., Dastan S., Ozakbas S.
Citations: Unknown, Year: 2023 - Switching to natalizumab or fingolimod in multiple sclerosis: Comparative effectiveness and effect of pre-switch disease activity
Authors: Spelman T., Horakova D., ÖZAKBAŞ S., Alroughani R., Onofrj M., Kalincik T., et al.
Citations: Unknown, Year: 2023 - Heterogeneity on long-term disability trajectories in patients with secondary progressive MS: a latent class analysis from Big MS Data network
Authors: Signori A., Lorscheider J., Vukusic S., Trojano M., Iaffaldano P., Hillert J., et al.
Citations: Unknown, Year: 2023 - The Preference-Based Multiple Sclerosis Index: an assessment of its psychometric properties and translation into Turkish
Authors: Kahraman T., Ozdogar A. T., Abasiyanik Z., Sagici O., Baba C., Ertekin Ö., et al.
Citations: Unknown, Year: 2023 - The Effect of Smoking on Inactivated and mRNA Vaccine Responses Applied to Prevent COVİD-19 in Multiple Sclerosis
Authors: Şen S., Arslan G., Tütüncü M., Demir S., Dinç Ö., GÜNDÜZ T., et al.
Citations: Unknown, Year: 2023 - Early predictors of disability in paediatric multiple sclerosis: evidence from a multi-national registry
Authors: Sharmin S., Malpas C. B., Roos I., Diouf I., Alroughani R., ÖZAKBAŞ S., et al.
Citations: Unknown, Year: 2022 - Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis
Authors: Zhu C., Zhou Z., Roos I., Merlo D., Kalincik T., ÖZAKBAŞ S., et al.
Citations: Unknown, Year: 2022 - Three doses of COVID-19 vaccines in multiple sclerosis patients treated with disease-modifying therapies.
Authors: Baba C., Ozcelik S., Kaya E., Samedzada U., Ozdogar A. T., Cevik S., et al.
Citations: Unknown, Year: 2022 - Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis.
Authors: Roos I., Malpas C., Leray E., Casey R., Horakova D., Havrdova E. K., et al.
Citations: Unknown, Year: 2022 - Relationship between presence of spinal cord lesion and restless legs syndrome in multiple sclerosis
Authors: Baba C., Ozdogar A. T., ÖZÇELİK S., KAYA E., ÖZAKBAŞ S.
Citations: Unknown, Year: 2022 - Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS
Authors: Kalincik T., Kister I., Bacon T. E., Malpas C. B., Sharmin S., Horakova D., et al.
Citations: Unknown, Year: 2022 - Severity of COVID19 infection among patients with multiple sclerosis treated with interferon-beta
Authors: Simpson-Yap S., Pirmani A., De Brouwer E., Peeters L. M., Geys L., Parciak T., et al.
Citations: Unknown, Year: 2022 - Factors related to restless leg syndrome in neuromyelitis optica spectrum disorder
Authors: Ozdogar A. T., KAYA E., Sagici O., Dastan S., Karakas H., Baba C., et al.
Citations: Unknown, Year: 2022 - Predictive ability of the original and short form of the activities-specific balance confidence scale and its individual items for falls in people with multiple sclerosis
Authors: Abasiyanik Z., Kahraman T., Baba C., Sagici O., ERTEKİN Ö., ÖZAKBAŞ S.
Citations: Unknown, Year: 2022 - Updated Results of the COVID-19 in MS Global Data Sharing Initiative: Anti-CD20 and Other Risk Factors Associated With COVID-19 Severity.
Authors: Simpson-Yap S., Pirmani A., Kalincik T., De Brouwer E., Geys L., Parciak T., et al.
Citations: Unknown, Year: 2022 - Epstein-Barr virus antibody in newly diagnosed multiple sclerosis patients and its association with relapse severity and lesion location.
Authors: Olmez O., Baba C., Abasiyanik Z., Ozakbas S.
Citations: Unknown, Year: 2022 - Confirmed disability progression as a marker of permanent disability in multiple sclerosis
Authors: Sharmin S., Bovis F., Malpas C., Horakova D., Havrdova E. K., Izquierdo G., et al.
Citations: Unknown, Year: 2022 - Effects and safety of exergaming in persons with multiple sclerosis during corticosteroid treatment: a pilot study
Authors: Ozdogar A. T., Baba C., Kahraman T., Sagici O., Dastan S., Ertekin Ö., et al.
Citations: Unknown, Year: 2022 - Comparison of late-onset and early-onset people with multiple sclerosis based on cognitive and physical assessments
Authors: Ozakbas S., Kaya E., Ozdogar A.
Citations: Unknown, Year: 2022 - Comparative Effectiveness and Persistence of Cladribine Tablets from GLIMPSE: Results from the MSBase Registry
Authors: Butzkueven H., Spelman T., Ozakbas S., Alroughani R., Terzi M., Hodgkinson S., et al.
Citations: Unknown, Year: 2022 - Sustained attention during prolonged walking in persons with multiple sclerosis
Authors: Abasiyanik Z., Kahraman T., Veldkamp R., Ertekin Ö., Kalron A., Ozakbas S., et al.
Citations: Unknown, Year: 2022 - Association of Latitude and Exposure to Ultraviolet B Radiation With Severity of Multiple Sclerosis An International Registry Study
Authors: Vitkova M., Diouf I., Malpas C., Horakova D., Havrdova E. K., Patti F., et al.
Citations: Unknown, Year: 2022 - Comparison of cognitive functions in relapsing and progressive multiple sclerosis patients on ocrelizumab treatment
Authors: Ozakbas S., Ozcelik S., Kaya E., Ozdogar T., Sagici O., Baba C.
Citations: Unknown, Year: 2022 - Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis
Authors: Lefort M., Sharmin S., Andersen J. B., Vukusic S., Casey R., Debouverie M., et al.
Citations: Unknown, Year: 2022 - Self-injectable DMTs in relapsing MS: NEDA assessment at 10 years in a real-world cohort
Authors: ÖZAKBAŞ S., ÇİNAR B. P., Baba C., Kosehasanogullari G.
Citations: Unknown, Year: 2022 - Real-World Comparative Effectiveness and Persistence of Cladribine Tablets and Other Oral Disease-Modifying Treatments for Multiple Sclerosis from GLIMPSE: Results from the MSBase Registry
Authors: Butzkueven H., Spelman T., Ozakbas S., Alroughani R., Terzi M., Hodgkinson S., et al.
Citations: Unknown, Year: 2022 - Restless legs syndrome and related factors in people with multiple sclerosis in Turkey
Authors: Özdoğar A. T., Ertekin Ö., Kahraman T., Baba C., Özakbaş S.
Citations: Unknown, Year: 2022 - The Turkish experience of COVID-19 infection in people with NMOSD and MOGAD: A milder course?
Authors: Sen S., Tuncer A., ÖZAKBAŞ S., Uzunkopru C., Baba C., Demir S., et al.
Citations: Unknown, Year: 2022 - Comparison of SARS-CoV-2 antibody response after two doses of mRNA and inactivated vaccines in multiple sclerosis patients treated with disease-modifying therapies
Authors: Özakbaş S., Baba C., Doğan Y., Cevik S., Özçelik S., Kaya E.
Citations: Unknown, Year: 2022 - Fatigue is associated with physical inactivity in people with multiple sclerosis despite different environmental backgrounds: Merging and comparing cohorts from Turkey and Israel
Authors: ÖZDOĞAR A. T., Kahraman T., ÖZAKBAŞ S., Achiron A., Kalron A.
Citations: Unknown, Year: 2022 - Challenges of persons with multiple sclerosis on ocrelizumab treatment during COVID-19 pandemic
Authors: Baba C., Yigit P., Dastan S., Hancer P., Sagici O., ÖZAKBAŞ S., et al.
Citations: Unknown, Year: 2022 - Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts
Authors: Sharmin S., Lefort M., Andersen J. B., Leray E., Horakova D., Havrdova E. K., et al.
Citations: Unknown, Year: 2021 - Long-term outcomes in patients presenting with optic neuritis: Analyses of the MSBase registry
Authors: Kenney R., Liu M., Patil S., Alroughani R., Ampapa R., Bergamaschi R., et al.
Citations: Unknown, Year: 2021 - Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis
Authors: Simpson-Yap S., De Brouwer E., Kalincik T., Rijke N., Hillert J. A., Walton C., et al.
Citations: Unknown, Year: 2021 - Utilization of Multiple Sclerosis Therapies in the Middle East Over a Decade: 2009-2018
Authors: Moradi N., Sharmin S., Malpas C., ÖZAKBAŞ S., Shaygannejad V., TERZİ M., et al.
Citations: Unknown, Year: 2021 - Effect of exergaming in persons with multiple sclerosis with restless legs syndrome: a randomized controlled trial
Authors: Ozdogar A. T., Ertekin O., Kahraman T., Aslan A. T., Dastan S., Ozakbas S.
Citations: Unknown, Year: 2021 - Comparatve effectveness of beta-nterferons and glatramer acetate on physcal and cogntve functons: 6-month follow-up study
Authors: Ozakbas S., Aslan T., Abasiyanik Z., Ozdogar A. T.
Citations: Unknown, Year: 2021 - Early predictors of disability in paediatric multiple sclerosis: evidence from a multi-national cohort
Authors: Sharmin S., Malpas C., Roos I., Diouf I., Alroughani R., Ozakbas S., et al.
Citations: Unknown, Year: 2021 - Comparative analysis of early treatment effectiveness of first-line disease-modifying therapies and fingolimod on cognitive functions in persons with multiple sclerosis
Authors: Yigit P., Sagici O., Abasiyanik Z., Baba C., Ozakbas S.
Citations: Unknown, Year: 2021 - External validation of the MSBase model of individual treatment response (Crystal Ball 1.0)
Authors: Moradi N., Sharmin S., Malpas C., Ozakbas S., Shaygannejad V., Terzi M., et al.
Citations: Unknown, Year: 2021 - Disease reactivation after cessation of disease-modifying therapy in relapsing-remitting multiple sclerosis
Authors: Roos I., Malpas C., Leray E., Casey R., Horakova D., Havrdova E. K., et al.
Citations: Unknown, Year: 2021 - Real-world experience with ocrelizumab in relapsing multiple sclerosis: insights from the MSOCR-R cohort, an MSBase registry sub-study
Authors: Butzkueven H., Spelman T., Ozakbas S., Boz C., Buzzard K., Skibina O., et al.
Citations: Unknown, Year: 2021 - Incidence and predisposing factors of COVID-19 in patients living with multiple sclerosis: Results from a prospective multiple sclerosis cohort
Authors: Ozakbas S., Berktas M., Aslan T., Baba C.
Citations: Unknown, Year: 2021 - Comparison of multiple disease modifying therapies in multiple sclerosis with marginal structural models
Authors: Diouf I., Malpas C., Sharmin S., Roos I., Horakova D., Havrdova E. K., et al.
Citations: Unknown, Year: 2021 - Comparison of early treatment response of ocrelizumab in relapsing and progressive multiple sclerosis patients on the basis of cognitive functions
Authors: Ozakbas S., Ozcelik S., Kaya E., Ozdogar A. T., Sagici O., Baba C.
Citations: Unknown, Year: 2021 - Comparison of the effectiveness of ocrelizumab vs interferons, fingolimod and natalizumab on relapses in relapsing-remitting multiple sclerosis
Authors: Roos I., Sharmin S., Ozakbas S., Horakova D., Havrdova E. K., Boz C., et al.
Citations: Unknown, Year: 2021 - Relapse during the washout period predicts time to relapse after switching to cladribine
Authors: Zhong M., van der Walt A., Hodgkinson S., Izquierdo G., Eichau S., Kalincik T., et al.
Citations: Unknown, Year: 2021 - Cognition as a parameter that should not be ignored when evaluating the effect of relapse treatment: A prospective controlled study
Authors: Cinar B., Baba C., Demir S., Uzunkopru C., Seferoglu M., Gungor Dogan I., et al.
Citations: Unknown, Year: 2021 - Real-world experience with cladribine in the MSBase Registry
Authors: Butzkueven H., Spelman T., Hodgkinson S., Madueno S. E., Izquierdo G., Buzzard K., et al.
Citations: Unknown, Year: 2021 - Relationship between presence of spinal cord lesion and restless legs syndrome in multiple sclerosis
Authors: Ozakbas S., Ozdogar A. T., Baba C., Ozcelik S., Kaya E.
Citations: Unknown, Year: 2021 - Associations between smoking and walking, fatigue, depression, and health-related quality of life in persons with multiple sclerosis
Authors: Kahraman T., ÖZDOĞAR A. T., Abasiyanik Z., ÖZAKBAŞ S.
Citations: Unknown, Year: 2021 - Determinants of therapeutic lag in multiple sclerosis
Authors: Roos I., Leray E., Frascoli F., Casey R., Brown J. W. L., Horakova D., et al.
Citations: Unknown, Year: 2021 - Does the reason for the switch to fingolimod affect the treatment response?
Authors: Ozakbas S., Aslan T., Ozdogar A. T., Abasiyanik Z., Sagici O.
Citations: Unknown, Year: 2021 - A comparative study of the effects of yoga and clinical Pilates training on walking, cognition, respiratory functions, and quality of life in persons with multiple sclerosis: A quasi-experimental study
Authors: Abasıyanık Z., Yiğit P., ÖZDOĞAR A. T., Kahraman T., ERTEKİN Ö., ÖZAKBAŞ S.
Citations: Unknown, Year: 2021 - Five-year real-world data on fingolimod treatment’s effects on cognitive function
Authors: ÖZAKBAŞ S., Piri Cinar B., Yigit P., Baba C., Sagici O.
Citations: Unknown, Year: 2021 - Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression
Authors: De Brouwer E., Becker T., Moreau Y., Havrdova E. K., Trojano M., Eichau S., et al.
Citations: Unknown, Year: 2021 - The effectiveness of natalizumab vs fingolimod–A comparison of international registry studies
Authors: Andersen J. B., Sharmin S., Lefort M., Koch-Henriksen N., Sellebjerg F., Sørensen P. S., et al.
Citations: Unknown, Year: 2021 - The relationship between cognition, depression, fatigue, and disability in patients with multiple sclerosis
Authors: Yigit P., Açıkgöz A., Mehdiyev Z., Dayı A., Özakbaş S.
Citations: Unknown, Year: 2021 - Effects of High- and Low-Efficacy Therapy in Secondary Progressive Multiple Sclerosis
Authors: Roos I., Leray E., Casey R., Horakova D., Havrdova E., Izquierdo G., et al.
Citations: Unknown, Year: 2021 - The outcome of a national MS-Covid-19 study: What the Turkish MS cohort reveals?
Authors: Sen S., Karabudak R., Schiavetti I., Demir S., Ozakbas S., Tutuncu M., et al.
Citations: Unknown, Year: 2021 - The efficacy of rituximab in patients with neuromyelitis optica spectrum disorder: A real-world study from Turkey
Authors: Uzunkopru C., Tutuncu M., Gunduz T., GÜMÜŞ H., Sen S., Demir S., et al.
Citations: Unknown, Year: 2021 - Cross-cultural adaptation and psychometric properties of the Turkish version of the Manual Ability Measure-36 (MAM-36) in people with multiple sclerosis
Authors: ERTEKİN Ö., Kahraman T., Aras M., Baba C., ÖZAKBAŞ S.
Citations: Unknown, Year: 2021 - Natalizumab, Fingolimod, and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis
Authors: Yeh W. Z., Widyastuti P. A., Van der Walt A., Stankovich J., Havrdova E., Horakova D., et al.
Citations: Unknown, Year: 2021 - Validity and reliability of “Cognitive Reserve Index Questionnaire” for the Turkish Population
Authors: ÖZAKBAŞ S., Yigit P., Akyuz Z., Sagici O., Abasiyanik Z., ÖZDOĞAR A. T., et al.
Citations: Unknown, Year: 2021 - High and low efficacy therapy in secondary progressive multiple sclerosis
Authors: Roos I., Leray E., Casey R., Horakova D., Havrdova E., Izquierdo G., et al.
Citations: Unknown, Year: 2021 - Association of Latitude and Exposure to Ultraviolet B Radiation with Severity of Multiple Sclerosis
Authors: Vitkova M., Diouf I., Malpas C., Horakova D., Havrdova E. K., Patti F., et al.
Citations: Unknown, Year: 2021 - Cross-cultural adaptation, validity and reliability of the Turkish version of the patient determined disease steps scale in persons with multiple sclerosis
Authors: Kahraman T., ÖZDOĞAR A. T., ÖZAKBAŞ S.
Citations: Unknown, Year: 2021 - Assessment of brain atrophy and lesion burden with clinical outcomes in multiple sclerosis real-world practice: The NeuroSTREAM MSBase retrospective, longitudinal study
Authors: Barnett M., Bergsland N., Weinstock-Guttman B., Butzkueven H., Kalincik T., Desmond P., et al.
Citations: Unknown, Year: 2021 - Disability Accrual in Primary Progressive & Secondary Progressive Multiple Sclerosis
Authors: Harding-Forrester S., Roos I., Sharmin S., Diouf I., Malpas C., Nguyen A., et al.
Citations: Unknown, Year: 2021 - Prevalence and determinants of falls in persons with multiple sclerosis without a clinical disability
Authors: Abasiyanik Z., Kahraman T., Ertekin Ö., Baba C., Özakbaş S.
Citations: Unknown, Year: 2021 - Delay from treatment start to full effect of immunotherapies for multiple sclerosis
Authors: Roos I., Leray E., Frascoli F., Casey R., William Brown J., Horakova D., et al.
Citations: Unknown, Year: 2021 - Comparative effectiveness of natalizumab and fingolimod in subgroups of patients with relapsing-remitting multiple sclerosis from three international cohorts
Authors: Sharmin S., Lefort M., Andersen J. B., Leray E., Horakova D., Havrdova E., et al.
Citations: Unknown, Year: 2021 - Prediction of on-treatment disability worsening in RRMS with the MAGNIMS score
Authors: Kunchok A., Lechner-Scott J., Granella F., Trojano M., Alroughani R., Sola P., et al.
Citations: Unknown, Year: 2021 - Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis
Authors: Minh Le M. L., Malpas C., Sharmin S., H
Citations: Unknown, Year: Unknown -
Brain atrophy and lesion burden are associated with disability progression in a multiple sclerosis real-world dataset using only T2-FLAIR: The NeuroSTREAM MSBase study
Barnett M., Bergsland N., Weinstock-Guttman B., Butzkueven H., Kalincik T., Desmond P., et al.
Year: 2021 | Citation Count/Metrics: PlumX Metrics -
Treatment Response Score to Glatiramer Acetate or Interferon Beta-1a
Bovis F., Kalincik T., Lublin F., Cutter G., Malpas C., Horakova D., et al.
Year: 2021 | Citation Count/Metrics: PlumX Metrics -
Balance and Gait Impairment in Persons with Multiple Sclerosis with the Absence of Clinical Disability
Ayan H., ERTEKİN Ö., Kahraman T., ÖZAKBAŞ S.
Year: 2020 | Citation Count/Metrics: PlumX Metrics -
Delay from treatment start to full effect of immunotherapies for multiple sclerosis
Roos I., Leray E., Frascoli F., Casey R., Brown J. W. L., Horakova D., et al.
Year: 2020 | Citation Count/Metrics: PlumX Metrics -
Explanatory factors of balance confidence in persons with multiple sclerosis: Beyond the physical functions
Abasiyanik Z., Özdoğar A. T., Sagici O., Kahraman T., Baba C., Ertekin Ö., et al.
Year: 2020 | Citation Count/Metrics: PlumX Metrics -
Effect of video-based exergaming on arm and cognitive function in persons with multiple sclerosis: A randomized controlled trial
ÖZDOĞAR A. T., ERTEKİN Ö., Kahraman T., Yigit P., ÖZAKBAŞ S.
Year: 2020 | Citation Count/Metrics: PlumX Metrics -
Early clinical markers of aggressive multiple sclerosis
Malpas C. B., Manouchehrinia A., Sharmin S., Roos I., Horakova D., Havrdova E. K., et al.
Year: 2020 | Citation Count/Metrics: PlumX Metrics -
Clinical and therapeutic predictors of disease outcomes in AQP4-IgG + neuromyelitis optica spectrum disorder
Kunchok A., Malpas C., Nytrova P., Havrdova E. K., Alroughani R., TERZİ M., et al.
Year: 2020 | Citation Count/Metrics: PlumX Metrics -
The effects of Clinical Pilates training on walking, balance, fall risk, respiratory, and cognitive functions in persons with multiple sclerosis: A randomized controlled trial
Abasiyanik Z., ERTEKİN Ö., Kahraman T., Yigit P., ÖZAKBAŞ S.
Year: 2020 | Citation Count/Metrics: PlumX Metrics -
Risk of secondary progressive multiple sclerosis: A longitudinal study
Fambiatos A., Jokubaitis V., Horakova D., Havrdova E. K., Trojano M., Prat A., et al.
Year: 2020 | Citation Count/Metrics: PlumX Metrics -
Determinant Role of Magnetic Resonance Imaging in Transition of Clinical Isolated Syndrome to Multiple Sclerosis
PİRİ ÇİNAR B., ÖZ D., BİRCAN KURŞUN B., GÜRKAN M., ÖZTÜRK O., ÖZAKBAŞ S.
Year: 2019 | Citation Count/Metrics: Hakemli Dergi -
The Determinant Role of Magnetic Resonance Imaging in Conversion from Clinically Isolated Syndrome to Multiple Sclerosis (Klinik İzole Sendromda Multipl Skleroza Dönüşümde Manyetik Rezonans Görüntülemenin Belirleyici Rolü)
PİRİ ÇİNAR B., ÖZ D., BİRCAN KURŞUN B., GÜRKAN M. A., ÖZTÜRK O., ÖZAKBAŞ S.
Year: 2019 | Citation Count/Metrics: Hakemli Dergi -
Comparative analysis of fingolimod versus teriflunomide in relapsing-remitting multiple sclerosis
BOZ C., TERZİ M., Ozer B., Turkoglu R., KARABUDAK R., EFENDİ H., et al.
Year: 2019 | Citation Count/Metrics: PlumX Metrics -
Effect of hormonal changes on the neurological status in the menstrual cycle of patient with multiple sclerosis
Yorgun Y. G., ÖZAKBAŞ S.
Year: 2019 | Citation Count/Metrics: PlumX Metrics -
The multiple sclerosis work difficulties questionnaire: translation and cross-cultural adaptation to Turkish and assessment of validity and reliability
Kahraman T., ÖZDOĞAR A. T., Honan C. A., ERTEKİN Ö., ÖZAKBAŞ S.
Year: 2019 | Citation Count/Metrics: PlumX Metrics -
The 20-year history: Change of multiple sclerosis patient profile over 20 years
ÖZAKBAŞ S., ÇİNAR B. P., Kahraman T.
Year: 2019 | Citation Count/Metrics: PlumX Metrics -
Monthly Pulse Methylprednisolone Therapy is Effective in Preventing Permanent Disease Progression in Secondary Progressive Multiple Sclerosis
ÖZAKBAŞ S., Cinar B. P., Oz D., Kosehasanogullari G., Kursun B. B., Kahraman T.
Year: 2019 | Citation Count/Metrics: PlumX Metrics -
Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis
Kalincik T., Havrdova E. K., Horakova D., Izquierdo G., Prat A., Girard M., et al.
Year: 2019 | Citation Count/Metrics: PlumX Metrics -
Frequency, type, distribution of pain and related factors in persons with multiple sclerosis’
Kahraman T., ÖZDOĞAR A. T., ERTEKİN Ö., ÖZAKBAŞ S.
Year: 2019 | Citation Count/Metrics: PlumX Metrics -
Cognitive involvement in clinically isolated syndrome and relationship with fatigue
ÇİNAR B. P., Yigit P., Gurkan M. A., Ozturk O., ÖZAKBAŞ S.
Year: 2019 | Citation Count/Metrics: PlumX Metrics -
Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis
Brown J. W. L., Coles A., Horakova D., Havrdova E., Izquierdo G., Prat A., et al.
Year: 2019 | Citation Count/Metrics: PlumX Metrics -
Effects of cigarette smoking on respiratory problems and functional levels in multiple sclerosis patients
Aktan R., ÖZALEVLİ S., ÖZAKBAŞ S.
Year: 2018 | Citation Count/Metrics: PlumX Metrics -
Relationship between Trunk Flexor Muscle Strength and Walking, Balance, and Falls in Multiple Sclerosis Patients (Multipl skleroz hastalarında gövde fleksör kas kuvvetinin yürüme,denge ve düşme ile ilişkis)
ABASIYANIK Z., ERTEKİN Ö., KAHRAMAN T., ÖZAKBAŞ S.
Year: 2018 | Citation Count/Metrics: Scopus -
Balance and Gait Disorder in Early Stages of Multiple Sclerosis (Multipl sklerozun erken evrelerinde denge ve yürüyüş bozukluğu)
AYAN H., ERTEKİN Ö., KAHRAMAN T., ÖZAKBAŞ S.
Year: 2018 | Citation Count/Metrics: Scopus -
Frequency, Type, Distribution of Pain and Related Factors in Individuals with Multiple Sclerosis (Multipl sklerozlu bireylerde ağrının sıklığı, tipi, dağılımı ve ağrıyla ilişkili etmenler)
KAHRAMAN T., ÖZDOĞAR A. T., ERTEKİN Ö., ÖZAKBAŞ S.
Year: 2018 | Citation Count/Metrics: Scopus -
Relationship between Respiratory Muscle Strength and Cognitive Functions in Multiple Sclerosis (Multipl sklerozda solunum kas kuvveti ile kognitif fonksiyonlararasında ilişki)
ABASIYANIK Z., ERTEKİN Ö., KAHRAMAN T., YİĞİT P., ÖZAKBAŞ S.
Year: 2018 | Citation Count/Metrics: Scopus -
The Effect of Clinical Pilates Training on Balance, Walking, Fall Risk, Respiratory Functions, and Cognitive Functions in Multiple Sclerosis Patients: A Randomized Controlled Trial (Multipl skleroz hastalarında klinik Pilates eğitiminin denge, yürüme,düşme riski, solunum fonksiyonları ve kognitif fonksiyonlar üzerineetkisi: randomize kontrollü çalışma)
ABASIYANIK Z., ERTEKİN Ö., KAHRAMAN T., ÖZAKBAŞ S.
Year: 2018 | Citation Count/Metrics: Scopus -
Prevalence of and risk factors for cognitive impairment in patients with relapsing-remitting multiple sclerosis: Multi-center, controlled trial
ÖZAKBAŞ S., Turkoglu R., Tamam Y., TERZİ M., Taskapilioglu O., YÜCESAN C., et al.
Year: 2018 | Citation Count/Metrics: PlumX Metrics -
Prediction of Conversion from Clinically Isolated Syndrome to Multiple Sclerosis According to Baseline Characteristics: A Prospective Study
Cinar B. P., ÖZAKBAŞ S.
Year: 2018 | Citation Count/Metrics: PlumX Metrics -
Smoking is associated with walking, fatigue, depression, and health-related quality of life in persons with multiple sclerosis
Ozdogar A., Kahraman T., ÖZAKBAŞ S.
Year: 2018 | Citation Count/Metrics: PlumX Metrics -
Long-term test-retest reliability and validity of the Six Spot Step Test in individuals with multiple sclerosis (Altı Nokta Adım Testi’nin multiple sklerozlu bireylerdeki uzun dönem test-tekrar test uyum ve güvenirliliği)
ÖZDOĞAR A. T., KAHRAMAN T., ERTEKİN Ö., ÖZAKBAŞ S.
Year: 2018 | Citation Count/Metrics: Scopus -
FEASIBILITY OF A 6-MONTH YOGA PROGRAM TO IMPROVE THE PHYSICAL AND PSYCHOSOCIAL STATUS OF PERSONS WITH MULTIPLE SCLEROSIS AND THEIR FAMILY MEMBERS
Kahraman T., ÖZDOĞAR A. T., Yigit P., Hosgel I., Mehdiyev Z., ERTEKİN Ö., et al.
Year: 2018 | Citation Count/Metrics: PlumX Metrics -
Upper Extremity Dysfunction in Multiple Sclerosis Patients without Clinical Disability (Klinik özürü olmayan Multipl skleroz hastalarında üst ekstremite fonksiyon bozukluğu)
ÖZDOĞAR A. T., KAHRAMAN T., ERTEKİN Ö., ÖZAKBAŞ S.
Year: 2018 | Citation Count/Metrics: Scopus -
Restless Legs Syndrome and Related Factors in Multiple Sclerosis Patients (Multipl sklerozlu hastalarında huzursuz bacak sendromu ve ilişkili faktörler)
ÖZDOĞAR A. T., KAHRAMAN T., YİĞİT P., HOŞGEL İ., ERTEKİN Ö., ÖZAKBAŞ S.
Year: 2018 | Citation Count/Metrics: Scopus -
The Effect of Video Game Based Physical Activity Approach on Upper Extremity Function, Walking, Balance, and Cognitive Functions in Multiple Sclerosis Patients: A Randomized Controlled Trial (Multipl skleroz hastalarında video oyunlari temelli fiziksel aktivite yaklaşımının üst ekstremite fonksiyonu, yürüme, denge ve kognitif fonksiyonlar üzerine etkisi: randomize kontrollü çalışma)
ÖZDOĞAR A. T., ERTEKİN Ö., KAHRAMAN T., YİĞİT P., ÖZAKBAŞ S.
Year: 2018 | Citation Count/Metrics: Scopus -
The Turkish validation of the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) battery
ÖZAKBAŞ S., Yigit P., Cinar B. P., Limoncu H., Kahraman T., Kosehasanogullari G.
Year: 2017 | Citation Count/Metrics: PlumX Metrics -
Intrathecal IgM index correlates with a severe disease course in multiple sclerosis: Clinical and MRI results
ÖZAKBAŞ S., Cinar B. P., KAYA ÖZÇELİK P., Baser H., Kosehasanogullari G.
Year: 2017 | Citation Count/Metrics: PlumX Metrics -
Monthly methylprednisolone in combination with interferon beta or glatiramer acetate for relapsing-remitting multiple sclerosis: A multicentre, single-blind, prospective trial
ÖZAKBAŞ S., Cinar B. P., Kosehasanogullari G., Kahraman T., Oz D., Kursun B. B.
Year: 2017 | Citation Count/Metrics: PlumX Metrics -
“No evidence of disease activity – cognition” in relapsing-remitting multiple sclerosis: recommendation for an extensive assessment of disease activity
ÖZAKBAŞ S., Cinar B. P., Yigit P., Kosehasanogullari G.
Year: 2017 | Citation Count/Metrics: SCI-Expanded -
Cognitive dysfunction in patients with multiple sclerosis treated with first-line disease-modifying therapy: a multi-center, controlled study using the BICAMS battery
Cinar B. P., Kosehasanogullari G., Yigit P., ÖZAKBAŞ S.
Year: 2017 | Citation Count/Metrics: PlumX Metrics -
Social Cognition in Multiple Sclerosis: a Meta-Analysis
BORA İ. E., ÖZAKBAŞ S., Velakoulis D., Walterfang M.
Year: 2016 | Citation Count/Metrics: PlumX Metrics -
Utilization of the Expanded Disability Status Scale as a distinctive instrument for walking impairment in persons with multiple sclerosis with mild disability
Kahraman T., SAVCI S., Poyraz E. C., ÖZAKBAŞ S., Idiman E.
Year: 2016 | Citation Count/Metrics: PlumX Metrics -
Paced auditory serial addition test: National normative data
ÖZAKBAŞ S., Cinar B. P., Gurkan M. A., Ozturk O., Oz D., Kursun B. B.
Year: 2016 | Citation Count/Metrics: PlumX Metrics -
Reassessment of Lhermitte’s sign in multiple sclerosis
BECKMANN Y., ÖZAKBAŞ S., Bulbul N. G., Kosehasanogullari G., SEÇİL Y., Bulut O., et al.
Year: 2015 | Citation Count/Metrics: PlumX Metrics -
Cognitive Impairment in Multiple Sclerosis: Historical Aspects, Current Status, and Beyond
ÖZAKBAŞ S.
Year: 2015 | Citation Count/Metrics: PlumX Metrics -
Determinants of physical activity in minimally impaired people with multiple sclerosis
Kahraman T., SAVCI S., Coskuner-Poyraz E., ÖZAKBAŞ S., Idiman E.
Year: 2015 | Citation Count/Metrics: PlumX Metrics -
Tau protein levels in the cerebrospinal fluid of the patients with multiple sclerosis in an attack period: Low levels of tau protein may have significance, too
Kosehasanogullari G., ÖZAKBAŞ S., Idiman E.
Year: 2015 | Citation Count/Metrics: PlumX Metrics -
Uveitis associated with multiple sclerosis: complications and visual prognosis
Kaya D., KAYA M., ÖZAKBAŞ S., Idiman E.
Year: 2014 | Citation Count/Metrics: PlumX Metrics -
Contingent Negative Variation Is Associated with Cognitive Dysfunction and Secondary Progressive Disease Course in Multiple Sclerosis
UYSAL U., Idiman F., Idiman E., ÖZAKBAŞ S., Karakas S., Bruce J.
Year: 2014 | Citation Count/Metrics: PlumX Metrics -
Early Deterioration In Quality Of Life And Physical Functioning Of Multiple Sclerosis Patients
ERTEKİN Ö., ÖZAKBAŞ S., İDİMAN E.
Year: 2014 | Citation Count/Metrics: Hakemli Dergi -
Caregiver burden, quality of life and walking ability in different disability levels of multiple sclerosis.
Ertekin Ö., ÖZAKBAŞ S., Idiman E.
Year: 2014 | Citation Count/Metrics: PlumX Metrics -
Evaluation of clinical parameters during and after treatment of attack in patients with clinically isolated syndrome: Comparison of the results with that of multiple sclerosis patients
Cinar B. P., ÖZAKBAŞ S., Idiman E.
Year: 2013 | Citation Count/Metrics: PlumX Metrics -
Importance of neutralizing antibody positivity in Turkish multiple sclerosis patients
KAYA D., TUFAN S., ÖZAKBAŞ S., BAHAR H., ADA E., İDİMAN E.
Year: 2013 | Citation Count/Metrics: PlumX Metrics -
Sexual dysfunction in multiple sclerosis: Gender differences
Celik D. B., Poyraz E. C., Bingol A., Idiman E., ÖZAKBAŞ S., Kaya D.
Year: 2013 | Citation Count/Metrics: PlumX Metrics -
The Comparison of Physical Activity Status, Exercise Perception and Quality of Life Between Clinically Isolated Syndrome and Multiple Sclerosis Patients
Ertekin Ö., ÖZAKBAŞ S., Cinar B. P., ALGUN Z. C., Idiman E.
Year: 2013 | Citation Count/Metrics: PlumX Metrics -
The Effects of Low and Severe Disability on Walking Abilities and Quality of Life in Multiple Sclerosis Patients: 6-Month Follow-up Study
Ertekin Ö., ÖZAKBAŞ S., Idiman E., ALGUN Z. C.
Year: 2013 | Citation Count/Metrics: PlumX Metrics -
Early onset multiple sclerosis has worse prognosis than adult onset multiple sclerosis based on cognition and magnetic resonance imaging
ÖZAKBAŞ S., KAYA D., Idiman E.
Year: 2012 | Citation Count/Metrics: PlumX Metrics -
Inflammatory demyelinating central nervous system diseases in childhood: Clinical and paraclinical profiles in 133 patients
Kaya D., Idiman E., ÖZAKBAŞ S.
Year: 2012 | Citation Count/Metrics: PlumX Metrics -
Quality of Life, Fatigue and Balance Improvements after Home-Based Exercise Program in Multiple Sclerosis Patients
ERTEKİN Ö., ÖZAKBAŞ S., Idiman E., ALGUN Z. C.
Year: 2012 | Citation Count/Metrics: PlumX Metrics -
Symptomatic Menagement in Multiple Sclerosis
Ozakbas S.
Year: 2011 | Citation Count/Metrics: PlumX Metrics -
The limited demyelinating diseases: the voyage of optic neuritis and transverse myelitis to multiple sclerosis and neuromyelitis
Idiman E., ÖZAKBAŞ S.
Year: 2011 | Citation Count/Metrics: PlumX Metrics -
Effect of cognitive function and physical activity on the ability to learn and reproduce physiotherapy exercises in healthy subjects
Kara B., GENÇ A., Colakoglu B. D., ÖZAKBAŞ S.
Year: 2011 | Citation Count/Metrics: SCI-Expanded -
A Case of Fever of Unknown Origin: Co-existence of Kikuchi-Fujimoto Disease and Acute Disseminated Encephalomyelitis (ADEM)
AVKAN OĞUZ V., Yapar N., ÖZAKBAŞ S., Demir-Onder K., Aktas E., ALP ÇAVUŞ S., et al.
Year: 2010 | Citation Count/Metrics: PlumX Metrics -
The significance of oligoclonal bands in multiple sclerosis: Relevance of demographic and clinical features, and immunogenetic backgrounds
Idiman E., Özakbaş S., Doğan Y., Kosehasanogullari G.
Year: 2009 | Citation Count/Metrics: PlumX Metrics -
Difference between generic and multiple sclerosis-specific quality of life instruments regarding the assessment of treatment efficacy
Ozakbas S., Akdede B. B., Kosehasanogullari G., Aksan O., Idiman E.
Year: 2007 | Citation Count/Metrics: PlumX Metrics -
Development of multiple sclerosis after vaccination against hepatitis B: a study based on human leucocyte antigen haplotypes
Ozakbas S., Idiman E., Yulug B., Pakoz B., Bahar H., Gulay Z.
Year: 2006 | Citation Count/Metrics: PlumX Metrics -
Motor assessment of upper extremity function and its relation with fatigue, cognitive function and quality of life in Multiple Sclerosis patients
Yozbatiran N., Baskurt F., Baskurt Z., Ozakbas S., Idiman E.
Year: 2006 | Citation Count/Metrics: PlumX Metrics -
Cross-cultural adaptation and validation of multiple sclerosis quality of life questionnaire (MSQOL-54) in a Turkish multiple sclerosis sample
Idiman E., Uzunel F., Ozakbas S., Yozbatiran N., Oguz M., Callioglu B., et al.
Year: 2006 | Citation Count/Metrics: PlumX Metrics -
Utilization of the multiple sclerosis functional composite in follow-up: relationship to disease phenotype, disability and treatment strategies
Ozakbas S., Ormeci B., Idiman E.
Year: 2005 | Citation Count/Metrics: PlumX Metrics -
Intrathecal sICAM-1 production in multiple sclerosis – Correlation with triple dose Gd-DTPA MRI enhancement and IgG index
Acar G., Idiman F., Kirkali G., Ozakbas S., Oktay G., Cakmakci H., et al.
Year: 2005 | Citation Count/Metrics: PlumX Metrics -
Visual evoked potential is superior to triple dose magnetic resonance imaging in the diagnosis of optic nerve involvement
Acar G., Ozakbas S., Cakmakci H., Idiman F., Idiman E.
Year: 2004 | Citation Count/Metrics: PlumX Metrics -
HLA genotypes in Turkish patients with myasthenia gravis: comparison with multiple sclerosis patients on the basis of clinical subtypes and demographic features
Donmez B., Ozakbas S., Oktem M., Gedizlioglu M., Coker I., Genc A. A., et al.
Year: 2004 | Citation Count/Metrics: PlumX Metrics -
Correlations between multiple sclerosis functional composite, expanded disability status scale and health-related quality of life during and after treatment of relapses in patients with multiple sclerosis
Ozakbas S., Cagiran I., Ormeci B., Idiman E.
Year: 2004 | Citation Count/Metrics: PlumX Metrics -
Utilization of the auditory consonant trigram test to screen for cognitive impairment in patients with multiple sclerosis: comparison with the paced auditory serial addition test
Ozakbas S., Ormeci B., Akdede B. B., ALPTEKİN K., Idiman E.
Year: 2004 | Citation Count/Metrics: PlumX Metrics -
Childhood and juvenile onset multiple sclerosis: clinical and paraclinical features
Ozakbas S., Idiman E., Baklan B., Yulug B.
Year: 2003 | Citation Count/Metrics: PlumX Metrics -
Nitric oxide as an activity marker in multiple sclerosis
Acar G., Idiman F., Idiman E., Kirkali G., Cakmakci H., Ozakbas S.
Year: 2003 | Citation Count/Metrics: PlumX Metrics
